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a b s t r a c t
Background: activation of the Wnt pathway by mutated APC gene is considered the initial 
event in colorectal carcinogenesis. The identifi cation of these mutations can improve the 
specifi c treatment of the adenocarcinoma. 
Objective: detect and evaluate wild-type APC protein in tissue from colorectal adenoma, 
adenocarcinoma and adjacent mucosa. 
Methods: 42 patients that underwent surgery for adenocarcinoma and 53 patients with re-
sected adenomas were studied. Tissue samples from the adenocarcinoma were obtained 
from the tumor and from adjacent non-neoplastic mucosa located 10 cm from the proxi-
mal margin of the tumor. Adenoma tissue was obtained from representative areas. Blocks 
of tissue microarray (TMA) were submitted to immunohistochemistry with anti-APC, with 
readings of positivity and intensity of immunostaining and the score of immune expres-
sion of APC protein was obtained. 
Results: the APC protein immune expression score showed a signifi cantly lower expression 
of APC protein in the adenoma when compared with the adenocarcinoma (p < 0.0001) and 
adjacent mucosa (p < 0.0001). The APC protein immune expression score in the colorectal 
mucosa and adjacent to the adenocarcinoma showed no signifi cant difference (p = 0.24). 
Conclusions: the fi nding of decreased expression of APC protein in adenoma tissue may indi-
cate that the mutated APC gene may contribute to the changes in the adenoma-carcinoma 
process of carcinogenesis sequence. The strong expression of protein APC in tissues from 
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Imunoexpressão da proteína APC nos tecidos de adenoma e de 
adenocarcinoma colorretais
Racional: a ativação da via Wnt pelo gene APC mutado é considerado  evento inicial da car-
cinogênese colorretal. A identificação dessas mutações pode tornar o tratamento do ade-
nocarcinoma mais específico. 
Objetivo: detectar e avaliar a proteína APC não mutada em tecidos de adenoma, adenocar-
cinoma e mucosa adjacente. 
Método: estudados 42 doentes operados de adenocarcinoma e 53 com adenomas resseca-
dos. Tecidos de adenocarcinoma foram obtidas da neoplasia e da mucosa adjacente não 
neoplásica situadas a 10 cm da margem proximal do tumor. Tecidos do adenoma foram 
obtidas de área representativa. Blocos de tissue microarray (TMA) foram submetidos a 
imuno-histoquímica com anticorpo anti-APC. Avaliadas a positividade e intensidade da 
expressão e obtidos  escores da imunoexpressão da proteína APC. 
Resultados: o escore da imunoexpressão da proteína APC no adenoma foi significantemente 
menor do que no adenocarcinoma (p < 0,0001) e na mucosa adjacente (p < 0,0001). O escore 
da imunoexpressão da proteína APC na mucosa adjacente e no adenocarcinoma não mos-
traram diferença significante (p = 0,24). 
Conclusões: a menor expressão da proteína APC no adenoma pode indicar que o gene APC 
mutado participa das alterações do processo adenoma-carcinoma. A forte expressão da 
proteína APC no CCR e na mucosa adjacente sugerem que a mutação do gene APC não 
participou da oncogênese.
the carcinoma and adjacent mucosa suggests that in most patients in this series, the muta-
tion of the APC gene did not participate in the oncogenesis mechanism.
Introduction
Colorectal cancer (CRC) is the second most common malig-
nancy in the West. Although 15-20% of CRC cases occur in 
the context of positive family history of the disease, specific 
genetic alterations in familial and sporadic adenocarcinomas 
are not yet completely known. 1
In sporadic CRC, mutations in the APC and k-ras genes and 
p53 protein are evident, but mutations in all three genes are 
rarely found in the same tumor. 2
APC gene comprises 108,352 bp at position 21q in chromo-
some 5 and has 21 exons encoding a protein with multiple 
functional domains that interact with proliferation and apop-
tosis regulators.3 
The gene is mutated in 63% of sporadic adenomas4 and in 
over 80% of sporadic CRC cases5 being inherent as heterozygous 
mutation in all cases of familial adenomatous polyposis (FAP).3 
The APC gene encodes a protein of 312 kDa with 2843 ami-
no acids. The APC gene inhibits the members of Wnt signaling 
pathway that promotes β-catenin expression as a stimulator 
of cell division within the intestinal crypts.6 A central region 
of APC protein is involved in β-catenin downregulation. This 
central region contains four segments with 15-amino acid re-
peats and seven segments with 20 amino-acid repeats.7 
A characteristic of the Wnt pathway activation is the 
nuclear accumulation of its main effector, the β-catenin, an 
activation component of the transcriptional complex that in-
cludes members of the TCF/LEF (T-cell transcription factor/
Lymphoid enhancer-binding factor), and consequently acti-
vating target genes in carcinogenesis.4,8,9,10
In detail, the activation of the Wnt pathway occurs when 
Wnt proteins bind to frizzled receptors and act as paracrine 
proteins starting transduction of several signaling pathways. 
The canonical Wnt signaling pathway stabilizes β-catenin 
transcription.11 The several domains of APC protein allow 
its interaction with numerous partner proteins, including 
β-catenin and axin, and is involved in several cellular pro-
cesses.10 The truncated APC protein disrupts the regulation 
of β-catenin-proteasome cellular concentration, blocking its 
degradation. The critical point is the β-catenin phosphory-
lation into Ser 33 and Ser 37 by phosphoglycerate dehydro-
genase, which catalyzes the first step in the biosynthesis of 
glycine inside the APC/axin complex, known as the “β-catenin 
destruction complex.” The Phospho-Ser33/37-β-catenin com-
plex comprises the recognition sequence for the ubiquitin 
subtype called E3 ligase βTrCP (β transduction repeat con-
taining protein), resulting in “ubiquitination” and subsequent 
degradation of β-catenin.9,10,11,12 
A functioning APC protein is thus vital in maintaining low 
levels of cytosolic β-catenin in the absence of Wnt signaling 
pathway, thereby preventing excessive cell proliferation.13 Al-
though the role of APC in the regulation of Wnt signaling is 
more important in the prevention of tumor initiation, its in-
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volvement in apoptosis and chromosomal stability also has 
an effect on adenoma growth progression.14  
Although surgery and chemotherapy are useful methods 
for the treatment of patients with CRC, additional strategies 
for the treatment of such patients are needed. It has become 
apparent that the accumulation of gene mutations in a clonal 
cell results in the transition from a normal colon epithelial 
cell into carcinoma.15 By defining the molecular alterations 
involved in the development of neoplasia, it is possible to ex-
pect the achievement of specific molecular targeting for the 
treatment of already established tumors, as well as for che-
moprophylaxis interventions.16
Method
Ethics
The study was approved by the Research Ethics Committee of 
Instituto de Assistência Médica ao Servidor Público Estadual 
de São Paulo (IAMSPE) (protocol N. 043/09) (Annex 10), by the 
Research Ethics Committee of Faculdade de Medicina do ABC 
(protocol N. 291/2007) (Annex 11) and by the Research Ethics 
Committee of Universidade Federal de São Paulo (UNIFESP) 
(protocol N. 815/09) (Annex 12). Permission to obtain tissue 
samples was obtained from the Department of Pathological 
Anatomy of Hospital do Servidor Público Estadual (HSPE), In-
stituto de Assistência Médica ao Servidor Público Estadual de 
São Paulo (IAMSPE) (Annex 13) and permission to perform 
immunohistochemical tests at the Molecular Pathology Lab-
oratory, Department of Pathology, EPM/UNIFESP (Annex 14). 
Permission to send the paraffin blocks to the Laboratory of 
Pathology, Faculdade de Medicina do ABC (Annex 15). 
Sample
A total of 64 patients with CRC and 53 patients with colorec-
tal adenoma were analyzed retrospectively. Patients with 
CRC were submitted to curative or palliative surgery at the 
Surgical Gastroenterology Service of HSPE and patients with 
adenoma underwent lesion removal by colonoscopy at the 
Endoscopy Sector of Faculdade de Medicina do ABC (Santo 
André, São Paulo, Brazil).
Patients were divided into Group 1, comprising 64 patients 
submitted to surgery for CRC, whose tissue samples were ob-
tained from the tumor and adjacent non-neoplastic colorec-
tal mucosa anteriorly located 10 cm from the upper margin of 
the tumor, and Group 2, comprising 53 patients undergoing 
colonoscopic removal of 71 adenomas.
Inclusion criteria were adult patients with CRC confirmed 
by histological analysis of the resected tumor with curative 
intention or palliative removal of the lesion. 
Exclusion criteria were patients younger than 18 years of 
age, patients with familial CRC or CRC associated with inflam-
matory bowel disease and patients submitted to emergency 
surgery and deficiency of the histological material used in the 
immunohistochemistry analysis. A total of 22 patients with 
CRC were excluded due to insufficient histological material 
for immunohistochemistry analysis, or due to detachment of 
the tissue. Thus, group 1 consisted of 42 patients with CRC 
that provided material considered adequate for immunohis-
tochemical analysis. In patients from group 2 that underwent 
resection of more than one adenoma, only the tumor with 
more marked histological alterations was considered for the 
analysis, totaling 53 adenomas. 
In group 1, 24 (57.1%) patients were males and 18 (42.9%) 
females. Mean age was 69.2 ± 7.4 years (51-90 years). The loca-
tion of the CRC was the colon in 27 (64.3%) cases and the rec-
tum in 15 (35.7%). The diameter of the tumors was ≥ 5 cm in 
21 (50%) patients and < 5 cm in 21 (50%). Of the 42 patients, 7 
(16.7%) with distal rectal adenocarcinoma underwent neoad-
juvant therapy. In group 2, regarding the adenomas obtained 
from 53 patients, 27 (50.9%) were males and 26 (49.1%) fe-
males. The mean age was 60.7 ± 3.4 years (29-88 years).
Staging was performed by complete clinical and anorectal 
examination, serum measurement of CEA and CA19-9, colo-
noscopy with lesion biopsy and respective histopathological 
analysis, opaque enema when indicated, and total abdominal 
and chest CT. The clinicopathological staging classification 
used was the TNM (UICC, 2010).17 
Resection with curative intent followed the pattern of on-
cologic surgeries. In palliative resections, the colorectal lesion 
was removed and oncologic procedures were not performed. 
Clinical characteristics were obtained from the sample for 
all groups of individuals. In the group of patients with colorec-
tal adenoma, the morphological characteristics of the lesion 
were recorded (location, histological type and degree of cell 
atypia). In patients with CRC, the following information was 
obtained: macroscopic characteristics of the lesion (location, 
size along the major axis), microscopic characteristics (level 
of invasion, inflammatory infiltrate, surgical margins, lymph 
node involvement, degree of tumor differentiation, lymphat-
ic/vascular invasion and neural infiltration), TNM classifica-
tion of UICC (2010),17 presence of synchronous metastases 
and immunostaining (staining intensity scores and percent-
age of stained cells) of anti-APC antibody in colorectal tissue.
Anatomopathological study
CRC tissues were fixed in formalin and routinely processed us-
ing the paraffin-embedding method for histological analysis. 
All pathological reports were analyzed to characterize macro-
scopic parameters. Histological sections with 3-μm thickness 
were obtained from each block. All slides were stained with 
hematoxylin-eosin (HE), revised by the pathologist and the 
diagnosis was confirmed.
In the stained slides, the best preserved areas that were 
representative of the tumor to obtain the building block (cyl-
inder) to be used in the preparation of tissue microarray (TMA) 
were identified.  For the construction of TMA, areas with ne-
crosis, hemorrhage, desmoplasia, and areas of low cellularity 
or even acellular areas were excluded. 
TMA preparation 
The TMA block was prepared using a Beecher ™ (Beecher In-
struments, Silver Spring, MD, USA) equipment, followed by the 
following steps: identification of the selected area in the re-
spective paraffin block; construction of the casela in the recipi-
ent block; extraction of 1 mm of tissue of the donor block from 
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the previously selected area of interest; obtaining cylinder tis-
sue from the donor block and placing it in the previously cre-
ated casela in the recipient block; progression into 1-mm frag-
ments to the new positions in the recipient block, thus creating 
a set of tissue samples obtained from the array arrangement 
and quality assessment of the final block for storage.
For adhesion of the TMA block section onto the slides, an 
adhesive tape system was used (Instrumedics, Hackensack, 
N.J., USA). Samples were cut at a thickness of 4 μm and a small 
cylinder was used to fix the tape. The histological section was 
subsequently joined, placed on a slide coated with resin and 
pressed with a cylinder to obtain better tissue section adhe-
sion. Then the slides with the histological cuts adhered to the 
tape were placed under UV light for 20 min, followed by im-
mersion in TPC solvent TM solution for another 20 min. After 
drying, the tapes were removed and the slides stored at -80 °C 
until completion of immunohistochemistry analysis. 
The antibody receptor blocks were obtained from two 
blocks, in which the first (A-TMA) was added to the adenoma 
tissue. In the second block (TMA-B), CRC and adjacent mu-
cosa cylinders were included. HE staining was performed in 
order to evaluate the quality of the sections and possible loss 
of sample representativeness.
Immunohistochemical analysis 
For the immunohistochemical study, 4-μm histological frag-
ments were obtained, placed on glass slides pretreated with 
3-aminopropyltriethoxysilane adhesive (Sigma Chemical Co, 
St. Louis, MO, USA). Initially, histological slides were placed in 
an oven at 60 °C for 24 hours to obtain better tissue adhesion 
and deparaffinization. Deparaffinization was performed in 
three xylene baths at room temperature for 15 min and placed 
after each of the three baths, in absolute ethanol baths in for 1 
min each. The slides were washed in running water for 5 min 
and submitted to heat induced antigen recovery by steam in a 
10 mM citrate buffer solution with pH 6.0 for 30 min. 
After cooling for 20 min at room temperature, the slides 
were washed in running water for 5 min and endogenous per-
oxidase blocking was performed using a hydrogen peroxide 
solution at 3%, in four baths of 5 min each. The slides were 
again washed in running water for 5 min and then washed 
with phosphate buffered saline (PBS), pH 7.2-7.6, also during 
5 min. 
Rabbit polyclonal anti-APC antibody C-20 (batch C1709) 
(Santa Cruz Biotechnology, Inc., CA, USA) was used, which de-
tects the wild-type APC protein and is recommended for de-
tection of the respective protein in human tissue. Incubation 
was carried out at a concentration of 1:100 in a humidified 
chamber at 4 ° C for at least 16-18 hours (overnight).
Subsequently, after three washes in PBS at pH 7.2 to 7.6, 
the incubation was performed with the streptavidin-biotin 
peroxidase kit (LSAB, DakoCytomation, CA, USA) in a humidi-
fied chamber at room temperature for 30 min. This step was 
followed by washes with PBS at pH 7.2-7.6 and development 
with liquid DAB (DakoCytomation, CA, USA) at room tempera-
ture for 5 min.  
After washing in running water for 3 min, counter-staining 
was performed with Harris hematoxylin for 1 min. The sec-
tions were dehydrated in three baths with absolute ethanol 
and three baths of xylene and then mounted using cover slips 
with Entellan resin (Sigma Chemical Co., St. Louis, MO, USA) 
for analysis by optical microscopy. 
As positive control, slides with histological sections pre-
viously demonstrated as being positive for these antibodies 
were used. A similar slide was used as a negative control, sub-
tracting the primary antibody from the reaction.
Immunoexpression score was prepared using the method 
by Hao.18 Slide positivity was considered zero score if there 
were less than 5% of epithelial cells in the lesion; score 1, with 
5% to 25%, score 2, with 26% to 50%, score 3, 51% to 75% and 
score 4, more than 75% of epithelial cells in the lesion. Inten-
sity was considered zero score when negative; score 1, when 
weak, score 2 when moderate and score 3, strong intensity.
The final score of the immunoexpression varied between 
zero and 12 and was obtained by multiplying the scores of in-
tensity and positivity. The immunoexpression was considered 
reduced when the final score was between zero and 8, and 
strong if the final score was between 9 and 12. 
Fig. 1 shows the adenoma tissue cells stained with anti-
APC antibody. Positivity in these slides was greater than 50% 
and the intensity was moderate to strong. 
Fig. 2 shows adenocarcinoma tissue cells stained with 
anti-APC antibody. Positivity in these slides was greater than 
75% and the intensity was strong. 
Statistical analysis 
The quantitative results were described as mean and stan-
dard deviation. Qualitative data was described as frequencies. 
The correlation between the scores of the immunohistochem-
ical expression of the APC protein with clinicopathological 
parameters was assessed by Spearman’s correlation coef-
ficient. Student’s t test, chi-square (χ2), Mann-Whitney test 
and McNemar test for paired variables were used to test the 
significance of differences in clinicopathological parameters.
Associations between positivity in protein labeling and clini-
copathological features of interest were evaluated by chi-
square or Fisher’s exact test (very small tables with frequen-
cies) or chi-square (χ2) of likelihood ratio (tables of variables 
with more than two categories). The univariate logistic regres-
sion analysis (ANOVA) and multivariate analysis were used 
to identify the dependent and independent variables. Signifi-
cance level was set at 5% (p ≤ 0.05). The statistical software 
SPSS, version 15.0 (The Predictive Analytics Company, Chica-
go, IL, USA) was used for statistical calculations.
Results 
Regarding the anatomopathological characteristics of CRC, 21 
(50%) patients had lymph node metastases, 13 (31%) had ve-
nous invasion, 13 (31%) had lymphatic vessel invasion and 6 
(14.3%) had neural and/or perineural infiltration. Thirty-four 
(81%) cases were classified as moderately differentiated, 7 
(16.7%) were well differentiated and 1 (2.3%) was poorly differ-
entiated. In relation to the depth of tumor invasion, 29 (69%) 
tumors were classified as T3, 12 (28.6%) as T2, and 1 (2.4%) as 
T4. Nine (21.4%) patients had metastases to the liver, perito-
neum, or both locations.
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Of the 42 CRC cases submitted to surgery, 39 (92.9%) under-
went curative resection and the median survival of these pa-
tients was 18.5 months. Neoplastic recurrence occurred in 10 
(23.8%) patients (2 colorectal adenocarcinomas and 8 colon ad-
enocarcinomas) and five of them (11.9%) died due to neoplasia.
Of the 71 adenomas removed from 53 patients, 64 (90.1%) 
were located in the descending colon, sigmoid colon and 
rectum and in the ascending colon or transverse colon in 
7 (9.9%). As for the histological type, the tumors were clas-
sified as tubular in 49 (69%) and tubulovillous lesions in 22 
(31%). Mild atypia was found in 39 (55%) adenomas and 32 
adenomas (45%) had no atypia. A total of 18 adenomas from 
patients with more than one adenoma were excluded at the 
immunohistochemical analysis. 
The positivity and intensity of the immunohistochemical 
expression of APC protein observed in the cytoplasm of 53 
colorectal adenomas studied are described in Tables 1 and 2. 
The intensity of the immunohistochemical expression 
of the APC protein observed in the cytoplasm in cases of 
adjacent non-neoplastic colorectal mucosa is described in 
Table 3. The intensity of the immunohistochemical expres-
sion of the APC protein found in the cytoplasm of the 42 CRC 
cases is described in Table 4. 
The positivity of the immunohistochemical expression of 
the APC protein in CRC and adjacent non-neoplastic mucosa 
was strong in all patients. 
The frequency of the APC protein in the colorectal ade-
noma tissues, of CRC and adjacent non-neoplastic colorectal 
mucosa is shown in Table 5. The frequency of strong expres-
sion was higher in tumor samples and adjacent non-neoplas-
tic colorectal mucosa than in samples of colorectal adenoma. 
The comparison of wild-type APC protein immunoexpression 
scores between adenoma and adenocarcinoma tissue showed 
that the immunoreactivity was significantly higher (p <0.0001) 
in adenocarcinoma tissue. The comparison of the scores of 
the wild-type APC protein immunoexpression between ad-
enoma tissue and adjacent non-neoplastic colorectal mucosa 
showed that the immunoexpression was significantly higher 
(p < 0.0001) in the adjacent non-neoplastic colorectal mucosa. 
The comparison of the scores of the wild-type APC protein 
immunoexpression in adenocarcinoma tissue and adjacent 
Fig. 2 – Photomicrograph of positive immunoexpression of 
anti-APC antibody represented by the brownish color in the 
cytoplasm of neoplastic cells from colorectal adenocarcinoma 
(immunohistochemistry; (A) 40x and (B) 400x).
Fig. 1 – Photomicrograph of positive immunoexpression 
of anti-APC antibody represented by the brownish 
color in the cytoplasm of cells from colorectal adenoma 
(immunohistochemistry; (A) 40× and (B) 400×).
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Regarding gender, in cases of adenomas with strong ex-
pression there were 13 (24.5%) women and 11 (20.7%) men, 
whereas in cases of adenomas with reduced expression there 
were 13 (24.5%) women and 16 (31.3% ) men (p = 0.58). 
Regarding the histological type, in adenomas with strong 
expression, 21 (39.6%) were tubular and 3 (5.6%) were tubulovil-
lous, whereas in adenomas with reduced expression, 16 (30.3%) 
were tubular and 13 (24.5%) were tubulovillous (p = 0.01).
In cases with adjacent non-neoplastic colorectal mucosa, 
there was one case with the reduced APC protein immunoex-
pression, without the possibility of statistical analysis regard-
ing age and sex.
In tumor tissue there were 38 (90.5%) patients with strong 
APC protein immunoexpression and 4 (9.5%) patients with 
reduced immunoexpression, and statistical analysis regard-
ing age and sex was not possible. In cases with strong APC 
protein immunoexpression, there were 22 (52.3%) women and 
16 (38.1%) men, whereas in tissues with CRC, reduced immu-
noexpression was found in 2 (4.8%) men and 2 (4.8%) women. 
Discussion
Luo et al.19 studied the formation of aberrant crypt foci as pre-
cursor lesions of colorectal carcinogenesis in normal human 
tissue. These authors observed normal expression of APC and 
β-catenin proteins, suggesting that loss of heterozygosity of the 
APC tumor suppressor gene, commonly seen in CRC, may occur 
earlier and perhaps even before the APC mutation. The findings 
of this study showed that the strong expression of wild-type APC 
protein in CRC tissues and adjacent non-neoplastic colorectal 
mucosa were found in most samples (90.4% and 97.6%, respec-
tively), a result that is in accordance with those by Luo et al.19 
A study on the influence of the Wnt signaling pathway 
in adenomas was performed by Wang et al.,20 who associ-
ated the presence of Wnt pathway activation to the process 
of carcinogenesis of laterally spreading tumors (LST). These 
authors studied 15 LST lesions and 54 adenomas and com-
pared the expression of GSK3-β, phospho-GSK3-β, axin and 
β-catenin proteins of the Wnt pathway in LST lesions and 
colorectal adenomas.
There was an increase in the expression of phospho-GSK3-β 
and β-catenin in LST lesions, but there was no difference in 
the expression of axin and GSK3-β proteins. These findings 
suggested that activation of the Wnt / β-catenin pathway 
seems to be more intense in LST lesions, when compared to 
colorectal adenoma. Hashimoto et al.21 studied 42 LST lesions, 
including seven colorectal adenomas, 25 intramucosal adeno-
carcinomas and 10 submucosal invasive colorectal adenocar-
cinomas. They found that the presence of the methylated APC 
protein was inversely proportional to the presence of submu-
cosal invasion in LST lesions. APC protein hypermethylation 
is significantly associated with the presence of APC muta-
tions.21,22 There was no association between APC gene muta-
tions and tendency to malignant LST lesions.21 In the present 
study, the wild-type APC protein expression was reduced in 
colorectal adenoma tissue, which may indicate tendency to 
malignant adenomas.20
Wong et al.3 studied 758 cases of colorectal adenomas lo-
cated in the distal large intestine represented by adenomas 
Table 5 – Frequency of scores of immunohistochemical 
expression of wild-type APC protein in adenoma tissue 
in adjacent non-neoplastic colorectal mucosa and 
colorectal adenocarcinoma. 
Scores Adenoma Adjacent 
Mucosa 
Tumor
Strong expression 24 (45.2%) 41 (97.6%) 38 (90.4%)
Decreased expression 29 (54.7%) 1 (2.4%) 4 (9.5%)
Table 1 – Intensity of immunohistochemical expression 
of wild-type APC protein in colorectal adenomas. 
Intensity n (%) 
Low 0 (0%)
Moderate 22 (41.5%)
Strong 31 (58.5%)
n, number of cases.
Table 3 – Intensity of immunohistochemical expression 
of wild-type APC protein in non-neoplastic adjacent 
colorectal mucosa in 42 patients with colorectal 
adenocarcinoma.  
Intensity n (%) 
Low 0 (0%)
Moderate 1 (2.4%)
Strong 41 (97.6%)
n, number of cases.
Table 4 – Intensity of immunohistochemical expression 
of wild-type APC protein in the 42 cases of colorectal 
adenocarcinoma. 
Intensity n (%) 
Low 0 (0%)
Moderate 2 (4.8%)
Strong 40 (95.2%)
n, number of cases.
Table 2 – Positivity of immunohistochemical expression 
of wild-type APC protein in 53 colorectal adenomas. 
Positivity n (%) 
< 5% 0 (0%)
5 to 25% 3 (5.7%)
26 to 50% 9 (17%)
51 to 75% 9 (17%)
> 75% 32 (60.3%)
n, number of cases.
non-neoplastic colorectal mucosa showed that immunoex-
pression was not significantly different (p = 0.24). 
In adenomas with strong expression (n = 24), the mean age 
was 62.3 ± 2.7 years, and in those with reduced expression, 
the mean age was 58.8 ± 1.94 (p = 0.29).
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greater than 1 cm in diameter, with villous element or high-
degree dysplasia, and other 767 cases of patients who under-
went flexible rectosigmoidoscopy with more than 90% of the 
colorectal mucosa located 50 cm above the anal border visible 
to the device without macroscopic alterations. These authors 
hypothesized that the relatively frequent (> 2%) presence of 
single nucleotide polymorphisms of the APC gene would pre-
dispose individuals to the formation of adenomatous polyps 
and CRC and found no association between the presence of 
polymorphisms and advanced distal adenomas or develop-
ment of sporadic adenomatous polyps in the colon. The au-
thors did not exclude the possibility of rarer variants of the 
APC gene contributing to the increased risk of developing 
CRC.3 
They concluded that malignant adenomas may not be 
related to the APC protein mutation alone, i.e., it is possible 
to develop colorectal carcinogenesis even in the absence of a 
truncated APC protein, which the results of the present study 
also suggested.
Yang et al.,23 in an experimental study in rats, found that 
colorectal carcinogenesis may occur even in the absence of 
the mutated APC protein. This process may be related to de-
creased production of mucin from goblet cells due to chronic 
inflammation process and stress of the colonic mucosa.23,24
Cleary et al.25 compared the presence of missense muta-
tions in the APC gene in 971 patients with CRC and 954 con-
trol cases. These authors observed that such a mutation oc-
curred in only 16 cases of CRC. They concluded that APC gene 
missense mutations have limited participation in the risk of 
developing CRC.
Foley et al.15 suggested that the suppression of β-catenin 
protein by target molecules such as oligodeoxynucleotide 
inhibits the formation of intestinal adenomas, even in the 
presence of truncated APC protein. This event could explain, 
in part, the finding of a few cases of wild-type APC protein 
weakly expressed in tissues of the adjacent non-neoplastic 
colorectal mucosa studied in the present series.
One of the most clinically relevant uses for anti-APC an-
tibodies is immunohistochemical analysis of tissues. APC 
protein was detected in the nucleus and cytoplasm of human 
colonic tissue, with more prevalent cytoplasmic staining in 
colon tumors when compared to normal tissues. Most anti-
APC antibodies currently available in the market have not 
shown to be specific for the identification of the APC protein 
and many commercially available clones of anti-APC recog-
nize an unidentified protein located in the apical region of 
polarized epithelial cells.26,27 This lack of specificity in some 
clones of anti-APC antibodies may have contributed to the re-
sults obtained in the present study.  
An antibody against the C-terminal portion of the APC 
protein that detects only full-length or wild-type APC protein 
and not a truncated form that originates from a mutation in 
the APC gene was used in the present study. When the APC 
protein is mutated, it loses its binding site in the β-catenin 
destruction complex, which usually results in increased ex-
pression of β-catenin in the cytoplasm and nucleus, which 
eventually results in decreased membrane expression.19 
Thus, the finding of decreased immunoreactivity of the 
wild-type APC protein in the majority of patients with colorec-
tal adenomas suggests that the APC gene participates in altera-
tions in colorectal adenoma formation. On the other hand, the 
substantial presence of wild-type APC protein in colorectal tu-
mor tissue and adjacent non-neoplastic colorectal mucosa in 
the significant majority of patients with CRC may indicate that 
the mutated APC protein did not participate in a significant 
way in the process of carcinogenesis in these patients.
Conclusions
The finding of an increased expression of wild-type APC 
protein in colorectal adenoma tissue may indicate that the 
mutated APC gene participates in the process changes of the 
adenoma-carcinoma sequence in colorectal carcinogenesis.
The strong expression of wild-type APC protein in tissues 
with CRC and in the adjacent non-neoplastic colorectal mu-
cosa suggests that, in the majority of patients in our series 
with colorectal carcinoma, the mutation in the APC gene did 
not participate in the mechanism of colorectal oncogenesis.
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